SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001517022-24-000070
Filing Date
2024-10-22
Accepted
2024-10-22 08:05:56
Documents
15
Period of Report
2024-10-22
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K akba-20241022.htm   iXBRL 8-K 31893
2 EX-99 akebiadocontract_finalx102.htm EX-99 35583
  Complete submission text file 0001517022-24-000070.txt   214394

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20241022.xsd EX-101.SCH 2139
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20241022_def.xml EX-101.DEF 3738
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20241022_lab.xml EX-101.LAB 25083
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20241022_pre.xml EX-101.PRE 14595
17 EXTRACTED XBRL INSTANCE DOCUMENT akba-20241022_htm.xml XML 2718
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 241384725
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)